key: cord-0751938-r517pahz authors: Ni, Shao-Qing; Fu, Qi-Bo; Shou, Xin-Yi; Shu, Qiang title: Take precautions beforehand: calling for clinical trials of pediatric drugs for treating coronavirus disease 2019 date: 2020-03-25 journal: World J Pediatr DOI: 10.1007/s12519-020-00355-3 sha: ce6b7057b5c0770edf527f36efc20c6119adbe0d doc_id: 751938 cord_uid: r517pahz nan by the National Health Commission of China is only available for adults in the field of antiviral treatments. The recommended antiviral drugs are interferon-α (IFN-α), lopinavir/ ritonavir, ribavirin, chloroquine diphosphate and arbidol [2] which have been used in the treatment of COVID-19 in adults. Based on the available evidences, IFN-α nebulization can be used in children, and it has shown good safety profiles under most circumstances. However, children are particularly sensitive to the accumulation of chloroquine phosphate in the body, which could possibly induce severe retinopathy, ototoxicity and cardiotoxicity. On the other hand, it lacks data on the safety of using lopinavir/ritonavir and abidor for children under 2 years of age. In the absence of adequate evidence for efficacy and safety, experts have not reached on an agreement on using ribavirin in the pediatric population. Guidelines for diagnosis and treatment of COVID-19 in children (Second Edition) recommend the use of IFN-α, lopinavir/ritonavir and ribavirin in children, without specifying age limitation [10] . The recommended dosage of ribavirin infusion varies in different medical literatures. Some suggest intravenous infusion of ribavirin administered at a dose of 10 mg/kg every time (maximum 500 mg every time), 2-3 times daily [10] , whereas others recommend 10-15 mg/ kg per day, divided into 2-3 times daily [11] . At present, the efficacy and safety, appropriate dosage, course of treatment and mechanism of action for children's anti-coronavirus drugs need to be studied, and that special attention should be paid to the particular adverse reactions and drug interactions in children [10] [11] [12] [13] . Based on the current epidemiological survey, the ages of the confirmed COVID-19 cases in children range from days to 17 years old. These children may have no clinical manifestations, such as fever, fatigue, dry cough, abdominal discomfort, nausea, vomiting, abdominal pain, diarrhea and other gastrointestinal symptoms, etc. A case of a 1.5-month-old infant diagnosed with COVID-19 experienced frequent vomiting [1, 2, 4, [14] [15] [16] [17] [18] . The clinical characteristics of COVID-19 in children are different from those in adults, and it is likely that differences also exist between children at different ages. It is unknown whether the disease process, treatment response and exposure response relationship of children with COVID-19 are like those of adults. According to the guidelines for clinical trials of pediatric drugs, it is not suitable to perform extrapolation on drug efficacy from adults to children. And children are not little adults. So comprehensive and systematic drug safety and efficacy clinical trials in pediatric population should be planned and conducted as early as possible once the clinical trial data of preliminary safety and potential benefits for adults have been acquired [19] . At present, more than 200 clinical trials for COVID-19 treatment have been carried out in medical institutions all over China. The drugs and the therapies include anti-AIDS drugs, influenza medications, glucocorticoid, traditional Chinese medicines/injections, stem cell transplantation, etc. However, drug clinical trials for COVID-19 children are very limited. As of February 28, 2020, one registered drug clinical trial of traditional Chinese medicine for the prevention of COVID-19 infection in children was found in the China Clinical Trial Registry Center; another clinical trial of darunavir and cobicistat for treatment of COVID-19 in children has been registered in ClinicalTrials.gov. The designs of the two clinical trials are not so scientific with unclear age range defined in the inclusion criteria. Although the proportion of infected children in the pediatric population to the whole population is relatively low, children are still at high risk of infection and should not be neglected. We should take precautions beforehand to carry out the clinical trials of pediatric drugs for the treatment of COVID-19. It should be emphasized that the ethical principles of pediatric clinical research must be followed before conducting pediatric clinical trials. Experimental drugs should be selected first from the drugs that have already been on the market and have been used in children. All clinical trials designed for pediatric population should follow the principle of "minimum sample size, and minimum pain" as much as possible [20, 21] . In conclusion, SARS-CoV-2 infected "COVID-19" is a new and pandemic disease. There are differences in clinical manifestations between children and adults. It is very necessary for the government, industries and institutes to prepare well in the early stage and to conduct clinical trials to evaluate the safety and efficacy of pediatric medications on the infected children. Author contributions All authors contributed to the initial discussion. NSQ wrote the first draft; FQB, SXY and SQ contributed papers and guidance to initial submission. After review and request for more information, SQ updated the document; all authors made final recommendations and edits.All authors approved the final version of the manuscript. Funding No funding was secured for this study. Ethical approval Not required for this paper. The authors have no conflicts of interest to disclose. First case of neonate infected with novel coronavirus pneumonia in China Novel coronavirus infection in hospitalized infants under 1 year of age in China Novel coronavirus-important information for clinicians First case of severe childhood novel coronavirus pneumonia in China A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster The National Health Commission of China. The Interim Guidance for Diagnosis and Treatment of COVID-19 infection (the Sixth version Why are children "missing" from coronavirus outbreak cases? LIVESCIENCE The State Council's Joint Prevention and Control Regulations for Pneumonia Outbreaks Caused by Novel Coronavirus Infection A contingency plan for the management of the 2019 novel coronavirus outbreak in neonatal intensive care units Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus Pharmaceutical care of antiviral drugs in children with new coronavirus pneumonia Chinese Journal of Pediatrics. Recommendations for the diagnosis, prevention and control of the 2019 novel coronavirus infection in children Working Group for the Prevention and Control of Neonatal 2019-nCoV Infection in the Perinatal Period of the Editorial Committee of Chinese Journal of Contemporary Pediatrics novel coronavirus infection Retracted: Clinical and epidemiological characteristics of 34 children with 2019 novel coronavirus infection in Shenzhen. Zhonghua er ke za zhi Analysis of CT features of 15 Children with 2019 novel coronavirus infection First case of 2019 novel coronavirus infection in children in Shanghai 2019-novel coronavirus infection in a three-month-old baby New coronavirus: new challenges for pediatricians National Medical Products Administration. Technical guidelines for drug clinical trials in pediatric population Special considerations for risk in pediatric clinical studies Informed consent for pediatric clinical studies